News

Published on 22 Sep 2022 on Benzinga via Yahoo Finance

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings


Article preview image

Citius Pharmaceuticals Inc (NASDAQ: CTXR) collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company, Inc. (NYSE: MRK) Keytruda (pembrolizumab) for recurrent or metastatic solid tumors.The investigator-initiated trial at UPMC is an open-label, Phase 1/1b study consisting of two parts.Part I is a dose escalation study of four cohorts and is expected to enroll 18-30 patients.Part 2 is a dose expansion study of approximately 40 patients to evaluate the safety and tolerability of the recommended combination dose of I/ONTAK and pembrolizumab.Related: Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm.The study will also investigate the alteration of the immune microenvironment within tumors and peripheral blood.Secondary endpoints include the objective response (complete response plus partial response), progression-free survival, and overall survival.University of Pittsburgh dose-ranging study is expected to begin in the fourth quarter of 2022.Additionally, Citius is collaborating with an investigator-initiated study at the University of Minnesota (UMN).This Phase 1 dose-finding study to evaluate I/ONTAK before Novartis AG's (NYSE: NVS) Kymriah (tisagenleucel) CAR-T therapy for diffuse large B-cell lymphoma (DLBCL) enrolled its first patient in May 2021.Price Action: CTXR shares closed 6.84% higher at $1.25 during after-hours trading on Thursday.

See more from Benzinga

NASDAQ.CTXR price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Citius Pharma Reports 2024 Financial Results and Business Update

Citius Pharma ( (CTXR) ) has released its Q4 earnings. Here is a breakdown of the information Cit...

TipRanks · via Yahoo Finance 30 Dec 2024

Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its...

Simply Wall St. · via Yahoo Finance 27 Dec 2024

Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin...

Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year Aft...

Benzinga · via Yahoo Finance 19 Aug 2024

Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

With the business potentially at an important milestone, we thought we'd take a closer look at Ci...

Simply Wall St. via Yahoo Finance 11 Feb 2024

Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its bus...

Simply Wall St. via Yahoo Finance 4 Sep 2023

Combination Therapy for Hemorrhoids: Citius' Combination Products Shows Meaningful Reduction In...

Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido, a topical treatment comprising lidocaine a...

Benzinga via Yahoo Finance 20 Jun 2023

When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its bus...

Simply Wall St. via Yahoo Finance 27 Mar 2023

After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc...

A downtrend has been apparent in Citius Pharmaceuticals, Inc. (CTXR) lately with too much selling...

Zacks via Yahoo Finance 28 Dec 2022

Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Ci...

Simply Wall St. via Yahoo Finance 18 Oct 2022

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

Citius Pharmaceuticals Inc (NASDAQ: CTXR) collaborated with the University of Pittsburgh for I/ON...

Benzinga via Yahoo Finance 22 Sep 2022